Targovax and Oslo University Hospital announce collaboration to test TG mutant RAS vaccination in multiple myeloma
· Targovax has entered into an agreement with Oslo University Hospital (OUS) to test TG01 in a phase 1/2 trial in 20 patients with RAS mutant multiple myeloma · The trial will be sponsored by OUS and led by Dr. Fredrik Schjesvold, an international leader in the field and founder of the Oslo Myeloma Center, the largest Myeloma center in the Nordics · The trial will be the first time TG vaccination is tested in patients together with the new adjuvant QS-21 STIMULON™ from collaboration partner AgenusOslo, Norway, 10 May 2022 – Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology